Abstract: A pharmaceutical composition comprises a drug component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The pharmaceutical composition further comprises a propellant component. The propellant component consists of one or more hydrofluorocarbon and hydrocarbon propellant compounds, at least 90 weight % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition. The pharmaceutical composition is in the form of a suspension and optionally comprises ethanol, but is free of other polar solvents/co-solvents.

Abstract: A pharmaceutical composition comprises a drug component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The pharmaceutical composition further comprises a propellant component. The propellant component consists of one or more hydrofluorocarbon and hydrocarbon propellant compounds, at least 90 weight % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition. The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents/co-solvents.

Abstract: A method for preparing a partially fluorinated alcohol, comprises reacting an epoxide: wherein R1, R2, R3 and R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl with a fluorinating agent.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

Abstract: The present invention relates to compounds according to formula (Ia) or formula (Ib); wherein each W is independently selected from the group consisting of H, F, Cl, Br, I and (CY2)mCY3; each Y is independently selected from the group consisting of F, Cl, Br and I; each Z is independently selected from the group consisting of H, OH, (CW2)pCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, (CW2)pOH, polyalkylene glycol and 15 polyolester; n is an integer from 2 to 49; m is an integer from 0 to 3; p is an integer from 0 to 9; the molecular weight average (Mw) is ?5500; and the polydispersity index is ?1.45; compositions comprising these compounds and methods for their production.

Abstract: A composition comprises (i) from about 2 to about 50% by weight 1,1-difluoroethene (vinylidene fluoride, R-1132a), (ii) from about 2 to about 95% by weight difluoromethane (R-32), and (iii) 2,3,3,3-tetrafluoropropene (R-1234yf).

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

Abstract: A fluorite synthetic stone comprises: (a) a glass matrix comprising Ca, Si and O, and having a predetermined weight ratio of Ca to Si; and (b) CaF2 crystals dispersed in the glass matrix at a concentration of at least about 70 wt.%. A method of making fluorite synthetic stones includes formulating a particulate mixture comprising: CaF2 crystals at a concentration of at least about 70 wt.%; and an excipient having a predetermined weight ratio of Ca to Si. Aggregates are prepared from the particulate mixture. The aggregates are heat treated to form a plurality of fluorite synthetic stones, where each synthetic stone comprises: a glass matrix comprising Ca, Si and O; and CaF2 crystals dispersed in the glass matrix at a concentration of at least about 70 wt.%.

Abstract: The invention provides a composition comprising 1,1-difluoroethene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf), optionally carbon dioxide (CO2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

Abstract: The present invention provides a process for preparing 3,3,3-trifluoropropene (1243zf), the process comprising: (a) fluorinating CCl3CH2CH2Cl (250fb) to produce a reaction product comprising CF3CH2CH2Cl (253fb) in the liquid phase in a first reactor, using HF as the fluorinating agent; and (b) (i) dehydrohalogenating 253fb to produce 1243zf in the vapour phase in the present of a catalyst in a second reactor; or (b)(ii) dehydrohalogenating 253fb to produce 1243zf in a second reactor, wherein the reaction product comprising 253fb produced in step (a) has subjected to one or more purification steps before step (b). The present invention also provides an azeotropic or near-azeotropic composition comprising HF and 253fb.

Abstract: A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one antiviral compound that is suitable for treating viruses that cause adverse effects in the lungs; and (ii) a propellant. The composition can be delivered to the lungs using a metered dose inhaler (MDI).

Abstract: A method for preparing a tetrafluoro-1,2-epoxypropane comprising reacting a 3-acetoxy-2-bromo-tetrafluoropropane with an alkaline or alkaline earth metal hydroxide solution to provide a tetrafluoro-1,2-epoxypropane, and partially fluorinated polyethers of formula [OCRR1CR2R3]n wherein n is from 5 to 100, R is F or H, R1 is CF3, R2 is F or H and R3 is H.

Abstract: The invention provides a composition comprising 1,1-difluoroethene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf), optionally carbon dioxide (CO2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Abstract: A refrigerant composition comprising carbon dioxide (CO2; R-744) and from 1 to 32 weight % difluoromethane (R-32) based on the total weight of the composition is described. Also described is the use of the refrigerant composition for providing heating and cooling and a refrigeration, air-conditioning or heat pump system comprising the refrigerant composition.

Abstract: A composition comprising a heat transfer portion and a lubricating portion, wherein the lubricating portion comprises one or more compounds according to formula (I) of the present disclosure, wherein W is H; Y is independently selected from the group consisting of F, Cl, Br and I; Z is independently selected from the group consisting of H, OH, (CW2)PCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, polyalkylene glycol and polyolester; n is an integer from 2 to 250; m is an integer from 0 to 3; and p is an integer from 0 to 9.

Abstract: The present invention relates to compounds according to formula (Ia) or formula (Ib); wherein each W is independently selected from the group consisting of H, F, Cl, Br, I and (CY2)mCY3; each Y is independently selected from the group consisting of F, Cl, Br and I; each Z is independently selected from the group consisting of H, OH, (CW2)pCW3, CY3, OCW3, O(CW2)pCW3, OCW((CY2)mCY3)CWCW2, (CW2)pOH, polyalkylene glycol and 15 polyolester; n is an integer from 2 to 49; m is an integer from 0 to 3; p is an integer from 0 to 9; the molecular weight average (Mw) is ?5500; and the polydispersity index is ?1.45; compositions comprising these compounds and methods for their production.

Abstract: The present disclosure provides compounds of formula (I), and preparation method thereof, wherein W is independently selected from the group consisting of H, F, Cl, Br and I; X is independently selected from the group consisting of H, F, Cl, Br, I, CW3 and OR on the basis that at least one X is OR; R is independently selected from the group consisting of C(O)CH2)m(CF2)nY and CW2C(CW2OC(O)(CH2)m(CF2)nY)3; m is an integer from 0 to 2;15 n is an integer from 2 to 8; Y is C(Z)3; and Z is independently selected from the group consisting of H, F, Cl, Br and I. Such compounds may be utilised as lubricants, for example in heat transfer compositions.

Abstract: A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).